Clarivate Reports Second Quarter 2026 Results
Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.
How this was made
The 30-second read
Why it matters
Traders should focus on the reconciliation between GAAP loss driven by a non-cash impairment and the adjusted profitability and cash generation, then map those to the expected benefits of the divestiture and deleveraging on 2026 margins and leverage.
Market read
This is a company-specific earnings and capital-structure update with a reaffirmed outlook, likely driving positioning around adjusted EBITDA, free cash flow trajectory, and the credibility/timing of the divestiture benefits.
What to watch
Investors may underweight the magnitude of free cash flow decline versus the prior year ($122.9M vs $160.6M) and the transactional revenue drop tied to customer migrations to subscription offerings.
Background
Clarivate is executing a Value Creation Plan and has previously announced a Life Sciences & Healthcare segment divestiture, while reporting Q2 2026 financial results and reaffirming its 2026 outlook.
Ticker impact
Clarivate reported Q2 2026 results, including a $221.7M non-cash goodwill impairment and reaffirmed 2026 outlook alongside a Life Sciences & Healthcare divestiture focus.
Near-term trading likely hinges on how investors weigh the impairment and organic revenue softness versus adjusted EBITDA, free cash flow, and the divestiture-driven focus.
The release provides concrete Q2 and first-half figures (revenues, adjusted net income, adjusted EBITDA, free cash flow) plus a reaffirmed outlook and a previously announced segment divestiture, which can shift expectations for margins and leverage.
Market effects
Could influence sentiment toward enterprise information-intelligence and subscription software peers by reinforcing a subscription mix and cost discipline narrative.
Limited direct regional impact; Clarivate is global and the story is company-specific.
Moderate, as the divestiture and leverage reduction may affect broader investor appetite for similar recurring-revenue software models.
Counterpoint
The goodwill impairment and organic revenue decline may signal underlying asset or demand pressure, and the divestiture may not fully offset near-term transactional weakness.
Key entities
- companyClarivate Plc
Reports Q2 2026 results, including adjusted earnings, cash flow, and a reaffirmed 2026 outlook alongside a Life Sciences & Healthcare divestiture focus.
